Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05008445 Terminated - Clinical trials for Advanced Solid Tumor

Study of LM-102 in Patients With Advance Solid Tumors

Start date: October 6, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label Phase I/II trial of LM-102 injection, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2). It is being tested in advanced solid tumors including gastric cancer/gastroesophageal junction adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, esophageal adenocarcinoma and ovarian mucous carcinoma.

NCT ID: NCT05005182 Terminated - Clinical trials for Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of luspatercept with or without hydroxyurea in treating patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts. Biological therapies, such as luspatercept, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Hydroxyurea may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving luspatercept with or without hydroxyurea may help doctors determine what doses of the combination is safe for patients to take and how the disease responds to the treatment.

NCT ID: NCT04958434 Terminated - Clinical trials for Metastatic Human Papillomavirus-Related Malignant Neoplasm

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Start date: June 11, 2021
Phase: Phase 1
Study type: Interventional

This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or metastatic cancers

NCT ID: NCT04949425 Terminated - Clinical trials for Advanced Solid Tumours

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Start date: September 13, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of adavosertib for patients enrolled in adavosertib clinical pharmacology studies (hereafter referred to as the 'parent studies') who continue to use the therapy

NCT ID: NCT04949191 Terminated - Clinical trials for Advanced Malignancies

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Start date: July 8, 2021
Phase: Phase 2
Study type: Interventional

Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.

NCT ID: NCT04945733 Terminated - Stomach Neoplasms Clinical Trials

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Start date: August 30, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the activity of amivantamab in gastric cancer (GC) and esophageal cancer (EC) participants (Phase 2a), and to characterize the preliminary antitumor activity of amivantamab in selected GC and EC population (Phase 2b).

NCT ID: NCT04928820 Terminated - Clinical trials for Metastatic Prostate Carcinoma

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Start date: June 16, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in detecting the spread of cancer to the bones (bone metastasis) in patients with prostate cancer and increased PSA after treatment (biochemical recurrence) during androgen deprivation therapy. Diagnostic procedures, such as 68Ga-PSMA-11 PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.

NCT ID: NCT04920383 Terminated - Lymphoma Clinical Trials

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

NEON-2
Start date: June 22, 2021
Phase: Phase 1
Study type: Interventional

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.

NCT ID: NCT04901806 Terminated - Solid Tumor, Adult Clinical Trials

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Start date: July 20, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.

NCT ID: NCT04897880 Terminated - Rhabdoid Tumor Clinical Trials

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

NORTH
Start date: January 9, 2019
Phase: Phase 2
Study type: Interventional

This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating patients with osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma.